Senores Pharmaceuticals Ltd. (SENORES) — Tipsheet

Senores Pharma targets 50-60% PAT growth after Q1 beat

Tipsheet Editorial — Mon, 27 Jul 2026 18:30:39 GMT

Revenue rose 36% to ₹180 cr, PAT up 56% to ₹31 cr. Management guided for full-year PAT growth of 50-60% and plans to commercialize 35 ANDAs over 18-20 months.

What’s new

Q1 consolidated revenue up 36% YoY to ₹180 cr, PAT up 56% to ₹31 cr
Management guides for full-year revenue growth of 30-40% and PAT growth of 50-60%
Plans to commercialize 35 ANDAs over next 18-20 months; defers large sterile injectable plant

Why it matters

The guidance points to sustained momentum in regulated markets, where ANDA approvals have nearly doubled to 58. The profitability-led reset in India branded generics and the deferral of sterile injectable capex suggest capital discipline. At a P/E of 50x, delivery on the 50-60% PAT guidance is priced in.

What we’re watching

Execution on the 35 ANDA launches over 18-20 months
Margins from the Aptyp plant ramp-up
Any further changes to the sterile injectable timeline

The full read

Senores Pharmaceuticals delivered a strong Q1. Revenue jumped 36% to ₹180 crore; PAT rose 56% to ₹31 crore. The regulated-markets engine, powered by a near-doubling of ANDA approvals to 58 and the Aptyp plant ramp-up, is firing. Management laid out an ambitious full-year path: 30-40% revenue growth and 50-60% PAT growth, with 35 ANDAs to commercialize over the next 18-20 months. It is also deferring a large sterile injectable project in favour of a pilot. That signals capital discipline. The stock trades at 50x trailing earnings, a multiple that demands delivery. But Q1 already lands at the top end of PAT guidance, making the target look credible rather than aspirational. Hardly a miss.

Primary source: BSE · NSE

Senores delays Atlanta plant, redirects ₹65 cr of IPO funds

Tipsheet Editorial — Mon, 27 Jul 2026 17:35:02 GMT

The sterile injectables facility at Atlanta won't be ready until Q4 FY28; the company now plans to use freed-up cash for ANDA buys and existing site expansions.

What’s new

CARE Ratings flags delay in Senores' sterile injectables plant at Atlanta, now due by Q4 FY28.
Shareholder approval sought to cut Atlanta allocation from ₹107 cr to ₹41.98 cr.
₹65.02 cr freed up will go toward ANDA acquisitions and expansion of Vadodara and Atlanta sites.

Why it matters

The delay and fund redirection are modest relative to Senores' ₹5,840 cr market cap and strong trailing growth. Still, any deviation from stated IPO use requires scrutiny; the revised plan focuses on nearer-term growth but extends the Atlanta facility timeline by at least a year.

What we’re watching

Whether shareholders approve the variation at the upcoming meeting.
Any further delays in the Atlanta plant timeline.
Update on ANDA pipeline acquisitions with the redirected funds.

The full read

Senores raised ₹500 crore in its December 2024 IPO, promising a sterile injectables plant in Atlanta. Now, seven months later, that plan has shifted. A CARE Ratings monitoring report shows the company deployed ₹399.46 crore of the proceeds by June 30, leaving ₹100.54 crore unspent. The Atlanta facility, originally due by fiscal 2027, has been pushed to the fourth quarter of fiscal 2028. In response, Senores wants shareholder approval to cut the Atlanta allocation from ₹107 crore to ₹41.98 crore and redirect ₹65.02 crore toward ANDA acquisitions and expansion of its Vadodara and Atlanta sites. The shift is small in the context of Senores' ₹5,840 crore market cap and 53% trailing revenue growth. It may reflect pragmatic capital allocation—buying ANDAs and scaling existing plants can generate returns faster than a greenfield facility. But it also means investors who bet on the Atlanta timeline will have to wait another year. The stock, trading at a P/E of 50.6x, already prices in fast growth. This filing does not change that story, but it adds a footnote: the company is spending its IPO money differently than it said it would.

Primary source: BSE · NSE

Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%

Tipsheet Editorial — Mon, 27 Jul 2026 15:49:02 GMT

Regulated markets lead with 42% growth as ANDA portfolio expands to 58 products; EBITDA surges 87% to ₹54 crore.

What’s new

Revenue of ₹180 cr, up 36% YoY; net profit ₹31 cr, up 56%.
EBITDA surged 87% to ₹54 cr, outpacing revenue growth.
Regulated markets segment grew 42% to ₹127.8 cr, driven by 58 ANDAs.

Why it matters

Senores is delivering consistent double-digit growth, with regulated markets now accounting for over 70% of revenue. The Baroda USFDA plant ramp-up adds further scale potential, though execution over the next 12-18 months will determine if margins remain strong.

What we’re watching

How quickly the Baroda plant scales to full capacity.
Timeline for commercializing the remaining 35 ANDAs.
Whether EBITDA margins can hold above 30%.

The full read

Senores Pharmaceuticals posted a strong first quarter for fiscal 2027, with revenue climbing 36% to ₹180 crore and net profit rising 56% to ₹31 crore. The regulated markets segment (the US and Canada) led the charge with 42% growth to ₹127.8 crore, powered by 58 approved ANDAs, of which 23 are now commercial. EBITDA surged 87% to ₹54 crore, pushing margins higher. Emerging markets also turned cash-flow positive on 30% revenue growth. Managing Director Swapnil Shah pointed to portfolio expansion, manufacturing efficiencies, and the ramp-up of the new Baroda USFDA plant as drivers. That facility should add more heft over the next year. At a market cap of ₹5,840 crore and a P/E of 50.6, the valuation already bakes in this trajectory. The next test is margin durability as the plant scales.

Primary source: BSE · NSE

Senores Q1 profit rises 56% on regulated markets growth

Tipsheet Editorial — Mon, 27 Jul 2026 15:42:00 GMT

Revenue up 36% to ₹180.2 cr, EBITDA surges 87%. Results in line with guided trajectory.

What’s new

Q1 net profit up 56% to ₹31 cr on revenue of ₹180.2 cr.
EBITDA surged 87% to ₹54 cr, margins up 800 bps.
Regulated markets revenue grew 42%, driven by ANDA portfolio.

Why it matters

The 800 bps margin gain reflects the benefit of scale as the ANDA portfolio grows. At a trailing P/E of 51x, the stock already prices in strong growth; execution must sustain.

What we’re watching

Whether the margin gains hold as ANDA launches continue.
Updates on USFDA inspections or pipeline milestones.
Management commentary on full-year guidance.

The full read

Senores Pharmaceuticals delivered a strong Q1 FY27. Consolidated revenue rose 36% to ₹180.2 crore, and net profit climbed 56% to ₹31 crore. The standout: EBITDA surged 87% to ₹54 crore, lifting margins by 800 basis points — a sign that scale from its ANDA-driven regulated markets business is showing through. That segment grew 42%. The board also classified AVP Finance Anjali Shah as senior management, a routine move. The numbers are in line with the trajectory management already laid out. At a trailing P/E of 51x, the market is paying for delivery. This quarter delivers. The next test is whether the margin gains hold as the pipeline grows.

Primary source: BSE · NSE

Senores' Q1: Revenue up 36%, profit up 56% — in line with guidance

Tipsheet Editorial — Mon, 27 Jul 2026 15:35:14 GMT

Strong growth but priced in. EBITDA margin expanded to nearly 30%. Anjali Shah appointed as senior management.

What’s new

Revenue rose 36% YoY to ₹180.21 crore
EBITDA surged 87% to ₹54 crore; net profit up 56% to ₹31 crore
Anjali Shah appointed as senior management personnel

Why it matters

The results confirm Senores' growth trajectory but were widely expected given prior guidance. With a trailing P/E of 50x, the valuation already reflects the momentum. The open question is whether the 30% EBITDA margin is sustainable.

What we’re watching

Whether revenue growth can sustain above 30%
EBITDA margin trajectory from the current ~30%
Any new product launches or regulatory updates

The full read

Senores Pharmaceuticals delivered a solid Q1 FY27. Revenue rose 36% YoY to ₹180.21 crore, net profit climbed 56% to ₹31 crore. EBITDA surged 87% to ₹54 crore, pushing the margin toward 30% — a sign of scale benefits. The company also named Anjali Shah to senior management, a routine update. These numbers matched guidance, so the filing adds nothing new. The stock's 50x trailing P/E already prices in the trajectory. The open question is whether the 30% EBITDA margin is sustainable or a low-base effect. Three more quarters will answer that.

Primary source: BSE · NSE

Senores Q1 profit surges 44% on regulated markets growth

Tipsheet Editorial — Mon, 27 Jul 2026 15:25:06 GMT

Revenue climbs 36% to ₹180 crore, but the numbers were well telegraphed in guidance.

What’s new

Revenue up 36% YoY to ₹180 cr, driven by regulated markets (+42%) and emerging markets (+30%).
Net profit rose 44% to ₹30 cr, consistent with prior quarters' strength.
Board approved Anjali Shah as senior management personnel from July 27, 2026.

Why it matters

The numbers continue a strong growth trend but are well within the company's own guidance. With a trailing P/E of 50.6, the stock already prices in this trajectory. The filing adds no new catalyst.

What we’re watching

Whether the regulated markets growth rate sustains above 40% through FY27.
Any update on the US specialty pipeline that could extend the earnings premium.
The pace of margin changes as revenue scales.

The full read

Senores delivered another quarter of solid execution. Revenue hit ₹180 crore, up 36% YoY. Net profit of ₹30 crore rose 44%. Regulated markets led at 42% growth. Hardly a surprise. All these numbers were well guided, and the market has already paid for this trajectory with a 50.6x trailing P/E that leaves little room for error. The open question is not this quarter's beat but whether the pipeline can sustain the premium that Senores commands in a sector where guidance rarely undershoots.

Primary source: BSE · NSE